Contemporary approaches to enhancing development of language structure, for younger children at least, are more likely to adopt milieu methods, in which the intervention is interwoven into natural episodes of communication, and the therapist builds on the childs utterances, rather than dictating what will be talked about. Interventions for older children, may be more explicit, telling the children what areas are being targeted and giving explanations regarding the rules and structures they are learning, often with visual supports.In addition, there has been a move away from a focus solely on grammar and phonology toward interventions that develop childrens social use of language, often working in small groups that may include typically developing as well as language-impaired peers.Another way in contemporary remediation differ from the past is that parents are more likely to be directly involved, but this approach is largely used with preschool children, rather than those whose problems persist into school age.For school-aged children, teachers are increasingly involved in intervention, either in collaboration with speech and language therapists/pathologists, or as the main agents of delivery of the intervention. Evidence for the benefits of a collaborative approach is emerging, but the benefits of asking education staff to be the main deliverers of SLT intervention (the "consultative" approach) are unclear. When SLT intervention is delivered indirectly by trained SLT assistants, however, there are indications that this can be effective.In this field, randomized controlled trial methodology has not been widely used, and this makes it difficult to assess clinical efficacy with confidence.
Sirolimus, a compound that inhibits mTOR signalling, is being studied to treat plexiform neurofibromas.The combination of erlotinib with sirolimus was studied to treat low-grade gliomas.Early research has shown potential for using the c-kit tyrosine kinase blocking properties of imatinib to treat plexiform neurofibromas.Peginterferon alfa-2b is being studied to treat plexiform neurofibromas.Sorafenib is being studied for treatment of unresectable plexiform neurofibroma and low-grade astrocytomas.In vitro, tranilast, inhibits growth of neurofibroma cells.Gene therapy for the neurofibromin 1 gene represents the ultimate solution to preventing the cluster of maladies which are enabled by the mutation. As of 2006, therapy for NF1 tumors had not been tested due to the lack of an appropriate NF1 tumor model. See also
Malignant peripheral nerve sheath tumor
Neurofibromatosis
Neurofibromin
Genetic disorder
Watson syndrome
Proteus syndrome
RASopathy
Palisaded encapsulated neuroma
Skin lesion
List of cutaneous conditions

References
External links

DermAtlas 67
"Neurofibroma" at Dorlands Medical Dictionary
Ferner RE, ODoherty MJ (December 2002). "Neurofibroma and schwannoma". Current Opinion in Neurology. 15 (6): 679–684. doi:10.1097/00019052-200212000-00004. PMID 12447105. S2CID 23782923.